Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1947 3
1949 2
1952 1
1954 1
1957 2
1958 12
1959 11
1960 27
1961 26
1962 64
1963 103
1964 179
1965 111
1966 124
1967 166
1968 212
1969 203
1970 219
1971 265
1972 288
1973 241
1974 302
1975 332
1976 328
1977 323
1978 354
1979 410
1980 427
1981 403
1982 496
1983 572
1984 644
1985 684
1986 721
1987 738
1988 837
1989 847
1990 857
1991 876
1992 961
1993 932
1994 1003
1995 1052
1996 1086
1997 1115
1998 1103
1999 1229
2000 1330
2001 1285
2002 1459
2003 1536
2004 1655
2005 1790
2006 1926
2007 1931
2008 2011
2009 2089
2010 2340
2011 2369
2012 2476
2013 2538
2014 2502
2015 2540
2016 2465
2017 2379
2018 2327
2019 2378
2020 2487
2021 2441
2022 2238
2023 1982
2024 1482

Text availability

Article attribute

Article type

Publication date

Search Results

67,421 results

Results by year

Filters applied: . Clear all
Page 1
Clinical pharmacology of 5-fluorouracil.
Diasio RB, Harris BE. Diasio RB, et al. Clin Pharmacokinet. 1989 Apr;16(4):215-37. doi: 10.2165/00003088-198916040-00002. Clin Pharmacokinet. 1989. PMID: 2656050 Review.
The recent development of clinically useful pharmacodynamic assays provides an attractive alternative to plasma drug concentrations, since these assays allow the detection of active metabolites of 5-fluorouracil in biopsied tumour or normal tissue. 5-Fluorouracil is …
The recent development of clinically useful pharmacodynamic assays provides an attractive alternative to plasma drug concentrations, since t …
5-Fluorouracil-associated cardiotoxicity.
Freeman NJ, Costanza ME. Freeman NJ, et al. Cancer. 1988 Jan 1;61(1):36-45. doi: 10.1002/1097-0142(19880101)61:1<36::aid-cncr2820610108>3.0.co;2-6. Cancer. 1988. PMID: 3275485 Review.
Cardiotoxicity manifested as myocardial ischemia is not generally recognized as a side effect of 5-fluorouracil. However, there have been at least 35 cases reported since 1975. ...
Cardiotoxicity manifested as myocardial ischemia is not generally recognized as a side effect of 5-fluorouracil. However, there have …
Antimetabolites.
Chen AP, Grem JL. Chen AP, et al. Curr Opin Oncol. 1992 Dec;4(6):1089-98. doi: 10.1097/00001622-199212000-00014. Curr Opin Oncol. 1992. PMID: 1457523 Review.
Research efforts over the past year further elucidate the determinants of sensitivity and mechanisms of resistance to the antimetabolites fluorouracil, methotrexate, and cytarabine. Progress has been made in clarifying the complex regulation of target enzyme expression for …
Research efforts over the past year further elucidate the determinants of sensitivity and mechanisms of resistance to the antimetabolites …
5-fluorouracil.
[No authors listed] [No authors listed] IARC Monogr Eval Carcinog Risk Chem Hum. 1981 May;26:217-35. IARC Monogr Eval Carcinog Risk Chem Hum. 1981. PMID: 6944260 No abstract available.
Topical chemotherapy.
Jansen GT. Jansen GT. Clin Dermatol. 1992 Jul-Sep;10(3):305-7. doi: 10.1016/0738-081x(92)90073-8. Clin Dermatol. 1992. PMID: 1483249 Review. No abstract available.
5-Fluorouracil nano-delivery systems as a cutting-edge for cancer therapy.
Valencia-Lazcano AA, Hassan D, Pourmadadi M, Shamsabadipour A, Behzadmehr R, Rahdar A, Medina DI, Díez-Pascual AM. Valencia-Lazcano AA, et al. Eur J Med Chem. 2023 Jan 15;246:114995. doi: 10.1016/j.ejmech.2022.114995. Epub 2022 Dec 1. Eur J Med Chem. 2023. PMID: 36493619 Review.
5-Fluorouracil (5-FU) is amongst the most commonly used antimetabolite chemotherapeutic agents in recent decades. ...
5-Fluorouracil (5-FU) is amongst the most commonly used antimetabolite chemotherapeutic agents in recent decades. ...
Fluorouracil: biochemistry and pharmacology.
Pinedo HM, Peters GF. Pinedo HM, et al. J Clin Oncol. 1988 Oct;6(10):1653-64. doi: 10.1200/JCO.1988.6.10.1653. J Clin Oncol. 1988. PMID: 3049954 Review.
Fluorouracil (5FU) is still considered the most active antineoplastic agent in the treatment of advanced colorectal cancer. ...
Fluorouracil (5FU) is still considered the most active antineoplastic agent in the treatment of advanced colorectal cancer. ...
Development of 5-Fluorouracil derivatives as anticancer agents.
Pan X, Wang C, Wang F, Li P, Hu Z, Shan Y, Zhang J. Pan X, et al. Curr Med Chem. 2011;18(29):4538-56. doi: 10.2174/092986711797287584. Curr Med Chem. 2011. PMID: 21864282 Review.
5-Fluorouracil (5-FU) is one of the most potent antimetabolites which have been widely used in the treatment of advanced solid tumors. ...
5-Fluorouracil (5-FU) is one of the most potent antimetabolites which have been widely used in the treatment of advanced solid tumors …
Mutual Prodrugs of 5-Fluorouracil: From a Classic Chemotherapeutic Agent to Novel Potential Anticancer Drugs.
Ciaffaglione V, Modica MN, Pittalà V, Romeo G, Salerno L, Intagliata S. Ciaffaglione V, et al. ChemMedChem. 2021 Dec 6;16(23):3496-3512. doi: 10.1002/cmdc.202100473. Epub 2021 Sep 7. ChemMedChem. 2021. PMID: 34415107 Free PMC article. Review.
Among broad-spectrum chemotherapeutics available for clinical use today, 5-fluorouracil (5-FU) is one of the most representative, also included in the World Health Organization model list of essential medicines. ...
Among broad-spectrum chemotherapeutics available for clinical use today, 5-fluorouracil (5-FU) is one of the most representative, als …
67,421 results
You have reached the last available page of results. Please see the User Guide for more information.